Asset profile
MC2-25
Small molecule
Evidence outlook · lead readout
NCT05482698 · Chronic Kidney Disease-associated Pruritus
The lead readout missed its primary endpoint. The grade and rationale below record what the trial was designed to show and what it found.
NCT05482698: This was a randomized, triple-blind (participant, investigator, and outcomes assessor), vehicle-controlled, parallel-group Phase 2 trial in 111 adults with CKD-associated pruritus. The primary endpoint was the mean change in the Worst Itch Numeric Rating Scale from baseline to Week 12; the published result shows a mean change of -3.70 in the MC2-25 group versus -3.87 in the vehicle group, indicating no benefit for MC2-25, with no p-value or confidence interval reported.
How the evidence outlook works ↗
Featured trials
Unlock featured-trial analysis
Research includes the instrumental studies, endpoints, key results, design grades, rationales and source links behind the Outlook.
Upcoming events
No upcoming readouts on record for this asset.
All registered studies
Unlock the complete ClinicalTrials.gov registry
Research includes every linked study, indication filters, phase grouping and featured-trial cross-links.
Competitive landscape
Unlock the competitor landscape
Research compares assets by shared mechanism and indication, including each competitor's stage in the relevant market.